Paper

Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR/Cas9 screening

Benes, Cyril, Yusa, Kosuke, Mcdermott, Ultan, Banerjee, Ruby, Matchan, Angela, Goncalves, Emanuel, Dow, David, Yang, Fentang, Picco, Gabriele, Bignell, Graham, Chen, Elisabeth, Iorio, Francesco, Saez-Rodriguez, Julio, Luz Garcia Alonso, Butler, Adam, Stronach, Euan, Fu, Beiyuan, Anderson, Elizabeth, Behan, Fiona, Garnett, Mathew

2019

Overview

Many gene fusions have been reported in tumours and for most their role remains unknown. As fusions can be used clinically for diagnostic and prognostic purposes, and are targets for treatment, it is crucial to assess their functional implications in cancer. To investigate the role of fusions in tumor cell fitness, we developed a systematic analysis utilising RNA-sequencing data from 1,011 human cancer cell lines to functionally link 8,354 gene fusion events with genomic data, sensitivity to >350 anti-cancer drugs and CRISPR-Cas9 loss-of-fitness information. Established clinically-relevant fusions were readily identified. Overall, functional fusions were rare, including those involving cancer driver genes, suggesting that many fusions are dispensable for tumor cell fitness. Novel therapeutically actionable fusions involving RAF1, BRD4 and ROS1 were verified in new histologies. In addition, recurrent YAP1-MAML2 fusions were identified as activators of Hippo-pathway signaling in multiple cancer types, supporting therapeutic targeting of Hippo signalling. Our approach discriminates functional fusions, identifying new drivers of carcinogenesis and fusions that could have important clinical implications.

• Publisher: Cold Spring Harbor Laboratory Press,Cold Spring Harbor Laboratory
• Subject: Cancer / Cancer Biology / Carcinogenesis / CRISPR / Data processing / Drug development / Fitness / Gene fusion / Ribonucleic acid / RNA / Signal transduction / Therapeutic targets / Tumor cell lines / Tumors / Yes-associated protein